Patient Journey Analytics and Insights
Pubrica provides patient journey analytics that reconstruct real-world care pathways for pharmaceutical companies, healthcare providers, payers and research organisations. We apply machine learning to each stage of the care pathway, including onset, diagnosis, treatment, adherence and outcome, using EHR and EMR records, claims, wearables and patient-reported data. Our data scientists reconstruct the pathway from the data you hold and indicate which steps the evidence supports. Deliverables include pathway maps, predictive models, reports and dashboards, so that your teams can act on the pathway patients actually follow rather than the one described in the guideline.
- Pathways reconstructed from several sources at once — EHR, EMR, claims, wearables and digital health apps — because no single source contains a whole journey
- Predictive models for adherence, progression and drop-off, validated on held-out data rather than reported on the set they were fitted to
- Treatment patterns and switching identified across structured and unstructured data, including the unmet need that shows up as a switch rather than as a complaint
- Natural language processing on free text — clinical notes, surveys and patient forums, where much of the patient journey is recorded but not coded
- Built under HIPAA and GDPR, with governance agreed before any patient-level data is transferred
Pathway reconstruction across sourcesIncluded
Adherence and drop-off modellingIncluded
Treatment pattern and switching analysisIncluded
Dashboards and reportingIncluded
Causation from observational dataAssociation only
Re-identifying individual patientsNever
Sources → linked → modelled → validated → acted on
- Governance settled before data moves
- Cohort definition written first
- Models validated on held-out data
- Association not reported as cause
- Dashboards you keep
Service Scope
Eight Patient Journey Analytics Services
Each project is scoped on the order. Cohort definitions and clinical interpretation remain with your clinicians.
From the pathway mapMedian 11.4 months from first symptom code to diagnosis, across four primary-care contacts. Two of the four carried a differential that was never followed up. That interval is the finding; the guideline assumes three months.
From the model reportAUC 0.91 reported on the training dataAUC 0.74 on a temporally held-out set, which is the number that means something. Calibration reported alongside discrimination, because a model that ranks well and is badly calibrated misleads at the threshold you would act on.
From the pattern analysis“Switch rate 18%.”18% switch within 6 months, and 71% of those switch after a specific adverse event that appears in the notes rather than in the coded data. The number needed NLP on free text to mean anything.
From the sentiment analysisForum data over-represents patients with a bad experience and under-represents those doing well. The report says so, weights where weighting is defensible, and does not present the result as a population estimate.
From the harmonisation noteTrial and RWD pooled into one analysis setHarmonised but analysed separately and compared. The trial population excluded the comorbidity that 41% of the real-world cohort has; pooling them would hide exactly the question you are asking.
From the modelling planClustering with the number of clusters chosen by stability across resamples rather than by silhouette on one fit. Clusters that do not reproduce are not reported as segments.
From the HEOR handoverResource utilisation by pathway stage, adherence by subgroup and time-to-treatment distributions — formatted as model inputs with their uncertainty, not as headline figures.
From the dashboard specFilter to a subgroup, see a rateEvery filtered view shows its denominator and greys out below a minimum cell size — for disclosure control, and because a 100% adherence rate on four patients is not a finding.
Samples are illustrative and anonymised. Hover any one of them to play it again.
Types of Patient Journey Analytics
Six Types of Patient Journey Analysis
These analyses overlap and are therefore offered as packages. The right package depends on how many data sources must be linked and whether free text is in scope.
Data we work with. EHR and EMR extracts, claims and billing data, wearables and remote monitoring, patient surveys and PROs, digital health platforms, clinical trial data and published literature. What we will not do: attempt re-identification, report a filtered view without its denominator, or present an association as a cause.
Who we serve
Six Client Groups We Support with Patient Journey Analytics
Each client group uses the analysis to inform a different decision, such as a care pathway, a launch plan, a coverage policy or a trial protocol, and each needs a different output.
Compliance and Standards
Data Protection and Reporting Standards for Patient Journey Analytics
Patient journey analytics must comply with data protection law first and research reporting standards second, because data protection determines which data the analysis can use.
HIPAA (De-identification and safe harbour)
What may be done with US patient-level data, and what de-identification has to achieve before anything else happens.
GDPR and UK GDPR (Lawful basis and processing)
Lawful basis, data minimisation and where processing may take place. This decides the project shape rather than being documented after it.
STROBE (For observational reporting)
How an observational study has to be reported. RECORD extends it for routinely collected health data, which is most of what this service uses.
TRIPOD+AI (BMJ, 2024)
Where a prediction model is developed or validated, this is the reporting standard — and it asks directly about validation and calibration.
ICMJE Recommendations (January 2026)
Where findings are published, including the declarations about data provenance and access.
Good Clinical Practice (ICH E6(R3), January 2025)
Where the work sits alongside a trial or feeds a regulatory submission.
Quality management (cert. H3CR9TCU20251212INDQM10N)
How the work is run, recorded and reviewed — not a data protection claim, and not presented as one.
Responsible Use of AI
Governance of Patient Data in AI-Assisted Analysis
Patient journey analytics uses data about real people, often under a specific legal basis. Governance is therefore part of the analysis itself, and governance decisions are made by people, not by tools.
Why we publish no accuracy figure of our own
Accuracy figures for AI tools are usually reported by the companies that sell them.
Pubrica therefore does not quote a self-generated accuracy figure, because it would carry the same conflict of interest. Instead, we tell you which tool was used on your project, at which stage, and what a human reviewer changed afterwards.
Methodology
How Our Patient Journey Analytics Process Works
No data is transferred until governance is agreed. The analysis then depends on how the cohort is defined, which is a clinical decision rather than a technical one.
Governance and cohort definition
The lawful basis, the consent position and where data may be processed are agreed first. The cohort definition is then written down before any data is queried, because a cohort defined after seeing the results would bias the findings.
Data collection and linkage
Patient data assembled from EMR and EHR, claims, wearables, surveys and digital platforms, and linked, with the match rate and the patients lost to linkage both reported.
Preparation and quality assessment
We harmonise coding, profile gaps and record the limitations of each source, because a gap in the source data remains a gap in the reconstructed journey.
Modelling and analysis
We carry out pathway reconstruction, predictive modelling, pattern analysis and NLP on free text, choosing methods for the question rather than applying a standard pipeline.
Validation
Models are tested on held-out data and, where possible, on temporally separate data, with calibration reported alongside discrimination. The out-of-sample performance is the figure we quote.
Reporting and handover
Findings are presented in clear reports and dashboards, with strategic implications kept separate from the findings so that you can accept one without adopting the other.
Request a Free Pathway Map for One Cohort
We reconstruct the pathway for one cohort with the touchpoints, drop-off points and data gaps marked, and add a note on which questions your data can and cannot answer. Two business days, no charge.
Please confirm governance before sending any data. Patient-level data is subject to a legal regime, and that regime, not the project timeline, decides where and by whom it may be processed.
Our experts
Your Patient Journey Analytics Team
A named team of subject specialists stays with your project from scoping to delivery. Your project coordinator introduces each member before work begins, and the handover records which of them completed each stage.
Reviews the scientific content for accuracy and confirms that each conclusion is supported by the evidence. Matched to your field rather than allocated from a rota.
Checks that statistical methods, tables and conclusions are consistent with the analysis plan and that the analysis can be reproduced.
Prepares, cleans and documents the data so that every step from raw data to final output can be traced and reproduced.
Independently checks code, tables and outputs against the analysis plan. Discrepancies are logged and resolved before delivery.
Sample work
Sample Work: Adherence Model, Before and After Validation
Step through the changes one at a time. The model is unchanged; what changes is how its performance is reported, and only the validated figures are a sound basis for decisions.
As first reported. A 12-month adherence prediction model on 18,000 linked patients.
- AUC 0.91
- “Validated by cross-validation”
- Prior adherence among the strongest predictors
- Accuracy 89%
- No calibration reported
- Cohort defined during the analysis
Validated. Same model, same data, reported so a decision can rest on it.
- AUC 0.74 on a temporally held-out year — the number to plan with
- Preprocessing fitted inside the folds — the 0.91 included leakage
- Prior adherence dropped — not available at the point of decision
- Accuracy is 89% because 88% adhere; PPV and recall reported instead
- Calibration plot included; the model over-predicts in the top decile
- Cohort definition written and frozen before querying
Figures illustrative; the therapy area, cohort size and values are changed. The pattern is the one we see most often.
Benefits
Benefits of Real-World Patient Journey Analysis
Each of these is checkable in your own report and dashboards. None is a causal claim, because observational data does not support one.
Packages
Patient Journey Analytics Service Packages
Each package is priced on the number of data sources to be linked, whether free text is in scope and the number of geographies involved. We therefore provide the free pathway map first.
Basic package
Small research teams and early-stage studies wanting a foundational view
Quoted per projectPriced on cohort size
Delivery 3–4 weeks
- ✓Data extraction from EMR/EHR, surveys and published sources
- ✓Patient demographics and treatment pattern analysis
- ✓Standard visualisation dashboards
- ✓Summary report of the key journey findings
- ✓Optional: custom data cleaning, advanced visualisation, regulatory alignment
Suited to questions that a single data source can answer.
View a sample Request a quoteAdvanced package
Pharma, biotech and providers needing predictive analysis
Quoted per projectPriced on sources linked
Delivery 5–7 weeks
- ✓Multi-source integration — EHR, wearables, claims, social and survey data
- ✓Predictive modelling of outcomes, validated out of sample
- ✓Sentiment and intent analysis from patient-reported data
- ✓Detailed journey mapping with touchpoints and drop-off analysis
- ✓Strategic insights report
- ✓Optional: platform integration, therapeutic-area benchmarking, stakeholder decks
Suited to projects that need several linked data sources.
View a sample Request a quotePremium package
Large pharmaceutical companies, CROs and global healthcare organisations
Quoted per projectPriced on geographies and refresh
Delivery 8–10 weeks
- ✓End-to-end mapping across geographies and therapeutic areas
- ✓Advanced ML — NLP, image recognition and deep learning
- ✓Real-time dashboards with interactive analytics
- ✓Comparative analysis across treatment regimens
- ✓Comprehensive reporting with strategic recommendations
- ✓Optional: API integration, monthly or quarterly refresh, expert consultation
Each market has its own governance requirements, so please name all geographies at scoping.
View a sample Request a quoteSend one de-identified cohort extract and we will map the pathway free of charge, with a note on what your data can and cannot answer. Ongoing monitoring is quoted against a schedule.
Quality Assurance
Our Service Commitments
Each commitment below states what we check, its limits and the remedy if the work does not meet the level on your order.
The Pubrica guarantee
Only Out-of-Sample Performance Is Reported
Every model is reported on data it was not fitted to, with calibration alongside discrimination and the threshold you would actually act on, because resources are committed on the basis of these figures.
01
Governance before data
Lawful basis, consent position and processing location are agreed first, because they determine how the project is designed.
02
Cohort defined before querying
Written and frozen in advance, so the definition is a study decision rather than a result.
03
Association is not reported as cause
Where the question is causal, the report says what design would answer it instead of implying this one has.
04
Free rework within the agreed scope, or a refund
Where the work does not meet the level on your order we do it again at no charge within the agreed scope, and where you would rather not, we refund it.
Client Testimonials
Patient journey FAQs
Patient Journey Analytics FAQs
If your question is not answered here, ask an expert — no quote required.
It makes the analysis feasible at the volumes involved. Linking millions of records across sources, reconstructing sequences and reading free text cannot be done manually at scale.
It does not change what can be inferred. These are observational data, so the results show association and sequence, not causation.
Electronic health records, clinical trial data, wearables and mobile apps, patient surveys and feedback, claims and billing data, and digital health platforms.
The linkage is usually the hard part. Match rates are never 100%, and the patients who fail to link are rarely a random sample — so the report states the rate and who was lost.
Pharmaceutical and biotech companies, hospitals and providers, medical device manufacturers, public health organisations, payers and insurers, CROs and HTA agencies.
The output differs between these groups. A hospital needs the intervals in its own pathway; a market access team needs model inputs with their uncertainty attached.
Understanding disease progression as it actually occurs, locating where adherence fails, informing R&D and trial design with real-world behaviour, and optimising treatment pathways against evidence rather than assumption.
A frequent and useful finding is a previously unmeasured interval, typically the time from first symptom to diagnosis and where that time is spent.
The lawful basis, the consent position and where processing may occur are agreed before any data is transferred. Data is de-identified to the applicable standard, with controlled access, encrypted transfer and no third-party tools.
Dashboards suppress small cells and always show denominators, both for disclosure control and because a rate calculated on four patients is not a reliable finding.
We can tell you what precedes it, how consistently, and in whom. That is association, and it is often enough to act on.
Observational data cannot establish cause. Where that is the real question, the report states which study design would answer it.
Related services
Related Data Analytics Services
This service reconstructs the patient pathway. The services below prepare the data, extend the modelling or turn the findings into a submission.
1DATA PREPARATIONbefore analysis
AI & data preparationCleaning, linkage, annotation and the documentation behind them. BiostatisticsAnalysis plans, reproducible code and the reporting.2HEALTH ECONOMICSeconomic evidence
Health economics & outcomes researchCost-effectiveness, budget impact and HTA dossiers. Predictive analyticsForecasting and risk models, validated and reported.3REPORTING AND PUBLICATIONpublication support
Interpretation & visualisationGuideline-compliant reporting and publication-ready figures. Scientific editingThe reporting-guideline check and the simulated review.Insights
Further Reading on Patient Journey Analytics
Request a Free Pathway Map for One De-identified Cohort
We mark the touchpoints, drop-off points and data gaps, and add a note on which questions your data can and cannot answer. Two business days, no charge.